MicroStrategy and Strive both increased their Bitcoin holdings in early November, with MicroStrategy purchasing 811 BTC and Strive adding 124 BTC. However, MicroStrategy issued 1.18 million new shares to raise $164 million, buying Bitcoin with only part of the funds, which diluted the Bitcoin exposure per share by about 0.17%. Meanwhile, Strive's share count stayed the same, increasing Bitcoin per share by 0.29%. MicroStrategy's ongoing share issuance and potential further dilution pose concerns for shareholders about the actual Bitcoin value represented per share despite growing holdings.
MicroStrategy and Strive's Bitcoin purchases provide context for cryptocurrency market activity on Pluang. For readers following crypto assets, here is Pluang's market snapshot as of Nov 02, 2026 20:43 WIB: out of 50 major cryptocurrencies, 8 rose and 41 fell. Among notable movers, YFI (Yearn) dropped 3.75% to Rp35,420,568 with a typical hold time of 94 days and a Pluang order activity skewed 73% Sell / 27% Buy, contrasting with CAKE (PancakeSwap) which fell 3.64% to Rp34,506 but saw 94% Buy activity and a shorter hold time of 75 days. EGLD (MultiversX) also declined 3.62% to Rp60,408 with 95% Sell orders and an 86-day hold time.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
